SAHA has been shown to enhance the sensitivity to PARP inhibitors in malignant tumors such as liver cancer and acute myeloid leukemia.[44] Treatment with SAHA combined with PARP inhibitors has only been sporadically reported for OC.[45] In this study, we used a variety of OC cell lines and PDX models with high KLF5 expression to confirm the treatment efficiency and mechanism of SAHA in inhibiting the transcription of RAD51. This evidence concerns the gene KLF5 and acute myeloid leukemia.